A phase 3, multi-center, prospective, randomized, placebo-controlled, delayed treatment, double-blind study to evaluate the effectiveness and safety of a single oral dose of 2 grams of secnidazole for the treatment of trichomoniasis in women

The objective of this study was to evaluate the efficacy and safety of single-dose secnidazole 2g oral granules in women with trichomoniasis. (Secnidazole is approved by the FDA to treat bacterial vaginosis).

Source: American Journal of Obstetrics and Gynecology - November 24, 2020 Category: OBGYN Authors: C.A. Muzny, J.R. Schwebke, P. Nyirjesy, G. Kaufman, L.A. Mena, G.B. Lazenby, O.T. Van Gerwen, K.J. Graves, J. Arbuckle, B.A. Carter, C.P. McMahon, J. Shaw, B. Pandey, S.E. Chavoustie Tags: IDSOG Oral Presentation Source Type: research